Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors

  • STATUS
    Recruiting
  • End date
    Aug 1, 2023
  • participants needed
    40
  • sponsor
    Shasqi, Inc.
Updated on 15 April 2021
Investigator
Principal Investigator
Primary Contact
Chris O'Brien Lifehouse (2.4 mi away) Contact
+5 other location
anthracyclines
primary cancer
solid tumour
solid tumor
metastatic solid tumor
solid neoplasm
metastatic malignant solid tumor

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of SQ3370 in patients with cancer (solid tumors).

Details
Condition Cancer, Cancer/Tumors, Ewing's Family Tumors, Cancer (Pediatric), Neoplasms, primary cancer, primary malignant neoplasm, malignancy, cancers, malignancies, malignant tumor, malignant tumors
Treatment SQ3370
Clinical Study IdentifierNCT04106492
SponsorShasqi, Inc.
Last Modified on15 April 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Diagnosis of an advanced local or metastatic solid tumor
Adequate hematologic, hepatic, renal, and coagulation function
Tumor is the type where published clinical data would suggest that anthracyclines have cytotoxic activity

Exclusion Criteria

CHF, severe myocardial insufficiency, or cardiac arrhythmia
Prior exposure to 300 mg/m^2 of Dox HCl or DOXIL / CAELYX or 600 mg/m^2 of Epirubicin HCl
Any of the following within 28 days prior to Cycle 1 Day 1
Major surgery, as defined by the Investigator
Radiotherapy
Currently enrolled in or discontinued from a clinical study involving an investigational agent or non-approved use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Chemotherapy, immunotherapy and/or anticancer therapy (except for small molecule kinase inhibitors, which are 6 elimination half-lives)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note